These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29093078)

  • 1. Radiographic Evidence of Hip Joint Recovery in Patients with Ankylosing Spondylitis after Treatment with Anti-tumor Necrosis Factor Agents: A Case Series.
    Song R; Chung SW; Lee SH
    J Rheumatol; 2017 Nov; 44(11):1759-1760. PubMed ID: 29093078
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
    Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
    Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintenance of Low Disease Activity following Tumor Necrosis Factor Inhibitor Dose Tapering in Ankylosing Spondylitis.
    Steel L; Gaffney K
    J Rheumatol; 2017 Aug; 44(8):1292. PubMed ID: 28765347
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.
    Ibáñez Vodnizza SE; Nurmohamed MT; Visman IM; van Denderen JC; Lems WF; Jaime F; van der Horst-Bruinsma IE
    J Rheumatol; 2017 Sep; 44(9):1355-1361. PubMed ID: 28711878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis.
    Lee JW; Kang JH; Yim YR; Kim JE; Wen L; Lee KE; Park DJ; Kim TJ; Park YW; Lee SS
    PLoS One; 2015; 10(7):e0131864. PubMed ID: 26176701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of ultrasound to monitor Achilles enthesitis in patients with ankylosing spondylitis during TNF-a antagonist therapy.
    Wang CH; Feng Y; Ren Z; Yang X; Jia JF; Rong MY; Li XY; Wu ZB
    Clin Rheumatol; 2015 Jun; 34(6):1073-8. PubMed ID: 25896532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
    Kim M; Won JY; Choi SY; Ju JH; Park YH
    Am J Ophthalmol; 2016 Oct; 170():32-40. PubMed ID: 27470062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
    Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
    Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Systemically Used Anti-Tumor Necrosis Factor-α Medication on the Corneal Epithelium and Stroma of Patients with Ankylosing Spondylitis.
    Arikan S; Gokmen F; Ersan I; Akbal A; Resorlu H; Gencer B; Ali Tufan H; Kara S
    Ocul Immunol Inflamm; 2017 Apr; 25(2):223-228. PubMed ID: 26731089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus.
    Schulte-Wrede U; Sörensen T; Grün JR; Häupl T; Hirseland H; Steinbrich-Zöllner M; Wu P; Radbruch A; Poddubnyy D; Sieper J; Syrbe U; Grützkau A
    Arthritis Res Ther; 2018 Aug; 20(1):191. PubMed ID: 30157966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
    Wang Y; Wang H; Jiang J; Zhao D; Liu Y
    Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy.
    Ilhan N; Ustun N; Tuzcu EA; Coskun M; Yagiz AE; Ilhan O; Parlakfikirer N
    Cutan Ocul Toxicol; 2015; 34(3):222-6. PubMed ID: 25363064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.